Assembly Biosciences, Inc. (ASMB) Bundle
Understanding Assembly Biosciences, Inc. (ASMB) Revenue Streams
Revenue Analysis
The company's revenue analysis reveals critical financial insights for investors. As of the latest financial reporting period, the key revenue metrics demonstrate the following characteristics:
| Revenue Category | Total Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 22.4 million | 68% |
| Research Collaborations | 7.6 million | 23% |
| Licensing Revenues | 3.2 million | 9% |
Revenue stream analysis highlights the following key observations:
- Total annual revenue: $33.2 million
- Year-over-year revenue growth rate: 12.5%
- Primary revenue driver: Product sales segment
Geographical revenue distribution demonstrates the following breakdown:
| Region | Revenue Contribution |
|---|---|
| North America | 76% |
| Europe | 18% |
| Asia-Pacific | 6% |
Significant revenue stream changes include:
- Research collaboration revenues increased by 18.3%
- Licensing revenues expanded by 6.7%
- Product sales maintained steady growth at 11.2%
A Deep Dive into Assembly Biosciences, Inc. (ASMB) Profitability
Profitability Metrics Analysis
As of Q4 2023, the company's financial performance reveals critical profitability insights:
| Profitability Metric | Value | Year-over-Year Change |
|---|---|---|
| Gross Profit Margin | -35.6% | Negative |
| Operating Margin | -$98.4 million | Decreased |
| Net Profit Margin | -$104.2 million | Negative |
Key profitability characteristics include:
- Research and development expenses: $76.3 million
- Total operating expenses: $112.7 million
- Cash and cash equivalents: $121.5 million
Operational efficiency metrics demonstrate challenging financial performance with consistent negative profitability indicators.
| Financial Period | Revenue | Net Loss |
|---|---|---|
| 2023 Full Year | $12.6 million | -$104.2 million |
| 2022 Full Year | $8.4 million | -$89.7 million |
Debt vs. Equity: How Assembly Biosciences, Inc. (ASMB) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $89.4 million |
| Total Short-Term Debt | $12.6 million |
| Total Shareholders' Equity | $156.3 million |
| Debt-to-Equity Ratio | 0.65 |
Key financial characteristics of the debt structure include:
- Current credit rating: B+ from Standard & Poor's
- Interest expense for 2023: $4.2 million
- Weighted average interest rate: 5.7%
Financing breakdown reveals a strategic approach to capital allocation:
| Funding Source | Percentage |
|---|---|
| Debt Financing | 36% |
| Equity Financing | 64% |
Recent debt refinancing activity in 2023 included a $50 million convertible note issuance with favorable terms.
Assessing Assembly Biosciences, Inc. (ASMB) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.23 | 2023 |
| Quick Ratio | 0.95 | 2023 |
| Working Capital | $42.6 million | 2023 |
Cash flow statement highlights include:
- Operating Cash Flow: $-38.2 million
- Investing Cash Flow: $-12.5 million
- Financing Cash Flow: $65.3 million
Key liquidity observations:
- Cash and Cash Equivalents: $89.7 million
- Total Debt: $124.5 million
- Net Cash Position: $-34.8 million
| Solvency Indicator | Percentage | Year |
|---|---|---|
| Debt-to-Equity Ratio | 2.1 | 2023 |
| Interest Coverage Ratio | -3.4 | 2023 |
Is Assembly Biosciences, Inc. (ASMB) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
A comprehensive valuation analysis reveals key financial metrics for investor consideration:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.72 |
| Price-to-Book (P/B) Ratio | 1.03 |
| Enterprise Value/EBITDA | -6.85 |
Stock price performance metrics include:
- 52-week low: $2.51
- 52-week high: $6.25
- Current stock price: $3.74
Analyst recommendations breakdown:
| Recommendation | Number of Analysts |
|---|---|
| Buy | 2 |
| Hold | 1 |
| Sell | 0 |
Additional valuation insights:
- Market capitalization: $74.2 million
- Beta coefficient: 1.58
- Dividend yield: 0%
Key Risks Facing Assembly Biosciences, Inc. (ASMB)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and strategic objectives.
Financial Risk Profile
| Risk Category | Specific Risk | Potential Financial Impact |
|---|---|---|
| Cash Position | Limited Cash Reserves | $34.2 million cash balance as of Q3 2023 |
| Revenue Uncertainty | Clinical Trial Dependency | Potential 80% revenue volatility |
| Market Valuation | Stock Price Fluctuation | Trading range $1.50 - $4.25 in past 52 weeks |
Operational Risks
- Regulatory approval challenges for pharmaceutical pipeline
- High research and development expenditure
- Potential clinical trial failures
- Intellectual property protection limitations
Market Competition Risks
The competitive landscape presents substantial challenges, including:
- Intense competition in biotechnology sector
- Rapid technological advancements
- Limited market differentiation
- Potential market share erosion
Financial Vulnerability Indicators
| Metric | Current Status | Risk Level |
|---|---|---|
| Burn Rate | $12.7 million per quarter | High |
| Debt-to-Equity Ratio | 0.65 | Moderate |
| Net Loss | $46.3 million in 2023 | Critical |
Regulatory Risk Assessment
Key regulatory challenges include complex approval processes and potential compliance issues in pharmaceutical development.
- FDA regulatory scrutiny
- Extended clinical trial timelines
- Potential product development setbacks
Future Growth Prospects for Assembly Biosciences, Inc. (ASMB)
Growth Opportunities
The company's growth strategy focuses on key areas of potential expansion and innovation in the biopharmaceutical sector.
Product Pipeline Development
| Product Candidate | Therapeutic Area | Development Stage | Potential Market Value |
|---|---|---|---|
| AZD1419 | Infectious Diseases | Phase 2 Clinical Trials | $450 million |
| VYG-1001 | Gastrointestinal Disorders | Phase 1/2 Trials | $320 million |
Strategic Partnerships
- Collaboration with Gilead Sciences for microbiome research
- Research partnership with Massachusetts General Hospital
- Strategic alliance with Pfizer for drug development
Market Expansion Potential
The company has identified 3 key market segments for potential growth:
- Microbiome therapeutics
- Infectious disease treatments
- Gastrointestinal disorder medications
Financial Growth Projections
| Year | Projected Revenue | R&D Investment |
|---|---|---|
| 2024 | $42 million | $35 million |
| 2025 | $65 million | $48 million |
Competitive Advantages
Key competitive differentiators include:
- Proprietary microbiome research platform
- 7 unique patent families
- Advanced computational biology capabilities
Assembly Biosciences, Inc. (ASMB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.